AbbVie (ABBV) had an eventful year, with a stock increase of
24%, many highs and lows, and an ongoing appeal to investors. The company also saw leadership changes, with a new R&D head and Chief Scientific Officer appointed. In a slew of acquisitions,
AbbVie absorbed companies like
Celsius Therapeutics and
Landos Biopharma, aiming to fortify its portfolio in areas like inflammatory and autoimmune diseases. FDA approval has been a mixed bag for the company, as it gained regulatory nods for numerous applications, including ones for
Upadacitinib and its Lymphoma drug, but faced repeated rejections for Parkinson's treatment due to issues with third-party manufacturers. Despite some stock dips,
AbbVie continues to show promise as a long-term value stock with a robust dividend offering. However, there's caution about purchasing for its next dividend payout. Concerns have also been raised around Humira sales slump, with the shortfall somewhat offset by new drugs. As per an analyst, there are chances of
AbbVie hitting the $200 market despite sluggishness. Even with challenges like ImmunoGen acquisition closure affecting its Q1 guidance, the firm looks set to grow post-Humira era.
Abbvie ABBV News Analytics from Thu, 30 Nov 2023 08:00:00 GMT to Fri, 12 Jul 2024 20:30:42 GMT -
Rating 2
- Innovation 1
- Information 6
- Rumor -5
